相关结果于2024年9月20日在线发表在Clinical Cancer Research期刊上，论文标题为“Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients”。研究中包含的四项临床试验评估了接受患者接受CAR-T细胞疗法治疗与标准治疗方案的疗效对比。在这...
最新数据：多线治疗无效后，CAR-T为患者带来71.4%临床获益率 摘要356：CLDN18.2 chimeric antigen receptor T cell therapy for patients with advanced gastric and pancreatic adenocarcinoma: Results of ELIMYN18.2 phase 1b clinical trial.研究背景：自体抗CLDN18.2（CLDN18.2）CAR-T细胞，即satri-cel（CT...
2. AACR2023:靶向CD70的异体CAR-T细胞有望治疗转移性透明细胞肾细胞癌 新闻:AACR: Novel allogeneic CAR T cell therapy delivers promising early results in patients with metastatic clear cell renal cell carcinoma由来自美国德克萨斯大学MD安德森癌症中心的研究人员领导的1期临床试验结果显示靶向CD70的异体嵌合抗原...
2023年7月18日最后一次随访时,肿瘤仍然得到很好的控制。 一名神经母细胞瘤患者在CAR-T细胞治疗后获得18年超长缓解 2025年2月17日,国际顶尖医学期刊《自然医学》发表了题为Long-term outcomes of GD2-directed CAR-T cell therapy in ...
新闻:AACR: Novel allogeneic CAR T cell therapy delivers promising early results in patients with metastatic clear cell renal cell carcinoma 由来自美国德克萨斯大学MD安德森癌症中心的研究人员领导的1期临床试验结果显示靶向CD70的异体嵌合抗原受体(CAR)T细胞(CAR-T)疗法ALL...
[1].Park, J.H., Nath, K., Devlin, S.M. et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med, 2023.https://doi.org/10.1038/s41591-023-02404-6
[1].Park, J.H., Nath, K., Devlin, S.M. et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med, 2023. https://doi.org/10.1038/s41591-023-02404-6 ...
新闻:AACR: Novel allogeneic CAR T cell therapy delivers promising early results in patients with metastatic clear cell renal cell carcinoma 由来自美国德克萨斯大学MD安德森癌症中心的研究人员领导的1期临床试验结果显示靶向CD70的异体嵌合抗原受体(CAR)T细胞(CAR-T)疗法ALLO-316在转移性透明细胞肾细胞癌(clear ...
新闻:AACR: Novel allogeneic CAR T cell therapy delivers promising early results in patients with metastatic clear cell renal cell carcinoma 由来自美国德克萨斯大学MD安德森癌症中心的研究人员领导的1期临床试验结果显示靶向CD70的异体嵌合抗原受体(CAR)T细胞(CAR-T)疗法ALLO-316在转移性透明细胞肾细胞癌(clear ...
[1]Mallapaty S. Cutting-edge CAR-T cancer therapy is now made in India - at one-tenth the cost. Nature. 2024 Mar;627(8005):709-710. doi:10.1038/d41586-024-00809-y. PMID: 38514877.[2]AACR: Novel allogeneic CAR T cell therapy delivers promising early results in patients with ...